Can-Fite BioPharma (CANF) investor relations material

Executive summary

• Achieved longer-than-anticipated overall survival in ongoing pivotal Phase III liver cancer study (Namodenoson).

• Durable survival outcomes observed in heavily pretreated pancreatic cancer patients in Phase 2a Namodenoson study; Phase IIb protocol in development.

• Completed enrolment of 247 patients in pivotal Phase 3 psoriasis study (Piclidenoson); interim analysis expected Q1 2027.

• Expanded global intellectual property portfolio with new patent allowances in key territories.

Financial highlights

• Revenues for H1 2026 were $0.20 million, unchanged year-over-year.

• Research and development expenses rose 13.86% to $3.45 million, driven by accelerated clinical activity.

• General and administrative expenses decreased 31.40% to $1.42 million, mainly due to lower investor relations costs.

• Net loss for H1 2026 was $4.60 million, down from $4.87 million in H1 2025.

• Cash and cash equivalents plus short-term deposits totaled $7.03 million as of June 30, 2026, down from $8.53 million at year-end 2025.

Outlook and guidance

• Interim analysis for pivotal Phase 3 psoriasis study expected in Q1 2027.

• Earlier interim analysis under consideration for Phase III liver cancer study due to longer-than-expected survival.

• General and administrative expenses expected to remain stable through 2026.